M
Mustang Bio
A fortress biotech Company
About Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company incorporated in 2015 and headquartered in Waltham, Massachusetts. A subsidiary of Fortress Biotech, Inc., the company is focused on developing and commercializing cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. The company's business model centers on acquiring rights to these technologies through licensing or ownership, funding their research and development, and then either out-licensing them or bringing them to market directly. To advance its pipeline, Mustang Bio has established partnerships with prominent medical institutions such as Fred Hutchinson Cancer Center, City of Hope National Medical Center, and Mayo Clinic.
The company was founded by Fortress Biotech, Inc. The leadership team includes President and CEO, Manuel Litchman, M.D., who joined in April 2017 after serving as President and CEO of Arvinas, LLC. Dr. Litchman has an extensive background in oncology, including leading a collaboration on CAR T-cell therapies at Novartis. Michael S. Weiss serves as the Executive Chairman of the Board.
Mustang Bio's therapeutic pipeline features several key candidates. A major focus is on Chimeric Antigen Receptor (CAR) T-cell therapies. One of its lead programs is MB-106, a CD20-targeted autologous CAR T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). Interim data from a Phase 1/2 trial of MB-106 showed a 90% overall response rate in patients with Waldenstrom macroglobulinemia, a rare blood cancer. The company is also developing CAR T therapies for solid tumors, including MB-101 for glioblastoma (GBM). Another program, MB-109, is a combination therapy using MB-101 (CAR T-cells) and MB-108 (an oncolytic virus) to treat glioblastoma. The strategy is to use the oncolytic virus to make the tumor microenvironment more receptive to the CAR T-cell therapy.
In the realm of gene therapy, Mustang Bio is developing MB-107, a lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID), also known as "bubble boy disease". XSCID is a rare genetic disorder that is fatal within the first year of life if untreated. MB-107 has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA). Phase 1/2 clinical trial data has been encouraging, supporting plans for a pivotal Phase 2 trial. The company's revenue is primarily derived from research and development activities and collaborations, as it is still in the clinical stage without commercial products. In May 2023, the company entered a strategic partnership with uBriGene (Boston) Biosciences, which included the sale of its Worcester manufacturing facility to reduce operating expenses and extend its cash runway.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2017
News
Open roles
Mustang Bio in the Waltham ecosystem
The Mustang Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Horizon Technology Finance Corporation
Runway Growth Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mustang Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mustang Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


